# Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

> **NCT03382977** · PHASE1,PHASE2 · TERMINATED · sponsor: **VBI Vaccines Inc.** · enrollment: 70 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **BIOLOGICAL:** VBI-1901
- **DRUG:** Carmustine
- **DRUG:** Lomustine

## Key facts

- **NCT ID:** NCT03382977
- **Lead sponsor:** VBI Vaccines Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-06
- **Primary completion:** 2025-07-30
- **Final completion:** 2025-08-30
- **Target enrollment:** 70 (ACTUAL)
- **Why stopped:** VBI Bankruptcy
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03382977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03382977, "Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects". Retrieved via AI Analytics 2026-08-08 from https://api.ai-analytics.org/clinical/NCT03382977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*